Navamedic ASA Reports Double-Digit Growth in Q3 2025
Navamedic ASA (OSE: NAVA), a Nordic pharma company, delivered revenues of NOK 138.9 million in Q3 2025, a 12.9% increase from Q3 2024.
The company's gross margin improved to 37.5%, compared to 37.1% in Q3 2024. Adjusted EBITDA amounted to NOK 11.3 million, up from NOK 8.6 million in 2024.
- Revenues: NOK 138.9 million (up 12.9% from Q3 2024)
- Gross margin: 37.5% (up from 37.1% in Q3 2024)
- Adjusted EBITDA: NOK 11.3 million (up from NOK 8.6 million in 2024)
No direct quote available in the text.
Author's summary: Navamedic ASA reports double-digit growth in Q3 2025, with revenues up 12.9%.